Welcome to our dedicated page for Urogen Pharma SEC filings (Ticker: URGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The UroGen Pharma Ltd. (URGN) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As an Israel-organized biotechnology issuer listed on The Nasdaq Stock Market, UroGen submits periodic and current reports that describe its financial condition, oncology pipeline, and corporate governance.
Investors can review Forms 10-K and 10-Q for detailed discussions of UroGen’s business, including its RTGel® reverse-thermal hydrogel platform, approved products for low-grade upper tract urothelial cancer and recurrent low-grade intermediate-risk non-muscle invasive bladder cancer, and revenue from product sales. These reports also outline research and development spending on programs such as UGN-103, UGN-104, and UGN-501, along with risk factors specific to urothelial and specialty cancer drug development.
Form 8-K filings provide timely updates on material events, such as quarterly financial results, executive compensation decisions, FDA approvals, and key commercialization milestones like the assignment of a permanent HCPCS Level II J Code (J9282) for ZUSDURI. Proxy materials on Schedule 14A describe annual meeting agendas, board elections, equity incentive plans, and advisory votes on executive pay and auditor engagement.
On Stock Titan, these filings are paired with AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly understand complex oncology, financial, and governance disclosures. Users can also access information relevant to insider and equity-related activity through compensation and equity plan discussions referenced in UroGen’s 8-K and DEF 14A filings.
UroGen Pharma (URGN) reported Q3 2025 results with revenue of $27,482 thousand, up from $25,204 thousand a year ago, as Jelmyto sales remained the primary driver and newly approved Zusduri contributed initial sales. Gross profit was $24,204 thousand. Operating expenses rose, led by selling, general and administrative costs of $37,582 thousand and research and development of $14,008 thousand, resulting in an operating loss of $27,386 thousand.
Net loss was $33,347 thousand (basic and diluted loss per share of $0.69). For the nine months, revenue reached $71,951 thousand with a net loss of $127,130 thousand. Cash, cash equivalents and marketable securities totaled $127.4 million as of September 30, 2025. The balance sheet reflected a prepaid forward obligation of $126,067 thousand and long‑term debt of $122,111 thousand. Shareholders’ deficit was $115,408 thousand.
Zusduri received FDA approval on June 12, 2025 and generated $1,779 thousand in Q3 sales, while Jelmyto delivered $25,703 thousand. Management stated that available cash and securities are expected to fund operations beyond one year from issuance. The company revised Q3 2024 loss per share to include 3,679,400 pre‑funded warrants in the weighted average shares outstanding.
UroGen Pharma (URGN) reported that it announced financial results for the quarter ended September 30, 2025. The details are provided in a press release furnished as Exhibit 99.1.
The information was furnished under Item 2.02 and is not deemed “filed” under Section 18 of the Exchange Act or incorporated by reference unless specifically stated. UroGen’s ordinary shares trade on Nasdaq under the symbol URGN.
Chris Degnan, Chief Financial Officer of UroGen Pharma Ltd. (URGN), reported equity changes related to restricted stock units. The reporting notes a grant of 13,450 RSUs on
Mark Schoenberg, Chief Medical Officer of UroGen Pharma Ltd. (URGN), received and settled restricted stock units in September 2025. On 09/07/2025 1,667 RSUs vested, each representing one ordinary share, increasing his beneficial ownership to 149,896 shares. On 09/08/2025 he sold 871 shares at $19.11 to satisfy withholding tax obligations, leaving him with 149,025 shares beneficially owned. The RSUs granted on 09/07/2023 totalled 5,000 and vest in three equal annual installments beginning 09/07/2024. The Form 4 was signed by an attorney-in-fact on 09/09/2025.
Insider transactions at UroGen Pharma Ltd. (URGN): Jason D. Smith, General Counsel, had 3,333 restricted stock units (RSUs) vest on 09/07/2025, which converted into 3,333 ordinary shares. On 09/08/2025 he sold 1,520 shares at $19.11 each to satisfy withholding tax obligations following the RSU settlement. After these transactions the reporting person beneficially owned 43,305 ordinary shares. The RSU grant referenced was originally for 10,000 shares, granted 09/07/2023 and vesting in three equal annual installments beginning 09/07/2024.
Form 144 notice for UroGen Pharma Ltd. (URGN) reports a proposed sale of 871 ordinary shares through Oppenheimer & Co. on 09/08/2025 with an aggregate market value of $16,444.48. The shares were acquired as RSUs on 09/07/2023 totaling 3,333 units for this grant, with payment recorded on the acquisition date. The filing also discloses two prior ordinary-share sales by the same seller in the past three months: 5,149 shares on 07/28/2025 for $98,551.86 and 5,162 shares on 06/09/2025 for $38,043.94. The filer affirms no undisclosed material adverse information about the issuer.
UroGen Pharma Ltd. (URGN) filing a Form 144 notifies a proposed sale of 1,520 ordinary shares through Oppenheimer with an aggregate market value of $28,697.60, scheduled approximately for 09/08/2025. The shares were acquired as RSUs on 09/07/2023 (6,666 units reported acquired at that time). The filer also reported a prior sale on 07/28/2025 of 7,522 ordinary shares generating $143,971.08 in gross proceeds. The notice includes the standard representation that the seller is not aware of any undisclosed material adverse information about the issuer. The form identifies the broker as Oppenheimer and shows ~46.26 million shares outstanding for the issuer.
UroGen Pharma insider grant: Director Daniel George was granted equity awards on 08/26/2025 consisting of a stock option to buy 10,000 ordinary shares at an exercise price of $19.50 and 8,000 restricted stock units (RSUs) each representing one ordinary share. The option and RSUs were reported as acquisitions and are held directly. The option and RSU awards vest in equal quarterly installments over one year, subject to the directors continuous service under the 2017 Equity Incentive Plan. The reporting was filed by an attorney-in-fact on 08/27/2025.
UroGen Pharma Ltd. (URGN) director James A. Robinson Jr. reported grants on 08/26/2025 consisting of a stock option and restricted stock units. The stock option is a right to buy 10,000 ordinary shares at an exercise price of $19.50 per share, exercisable through 08/26/2035. The RSUs represent a contingent right to 8,000 ordinary shares. Both the option shares and RSU shares vest in equal quarterly installments over one year, subject to the director's continuous service under the 2017 Equity Incentive Plan. The Form 4 was signed by an attorney-in-fact on 08/27/2025.
Holden Stuart, a director of UroGen Pharma Ltd. (URGN), received equity awards on 08/26/2025. The Form 4 reports a stock option for 10,000 ordinary shares with a stated price of $19.50 and 8,000 restricted stock units (RSUs), both granted on 08/26/2025. The Form shows 10,000 stock options and 8,000 RSUs beneficially owned following the reported transactions, each held in a direct ownership form. The disclosures state both the option and RSU awards vest in equal quarterly installments over one year, subject to Continuous Service under the 2017 Equity Incentive Plan. The Form 4 is signed by an attorney-in-fact on 08/27/2025.